Atrial Fibrillation Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 18 and 80 years old.
- People who have persistent atrial fibrillation (an irregular heart rhythm lasting more than 90 days) that causes symptoms such as palpitations, near-fainting, fainting, tiredness, or shortness of breath.
- People whose atrial fibrillation has not responded well to at least one heart rhythm medication, or who could not tolerate it, or for whom it was medically unsuitable.
- People who are having their first-ever procedure to treat atrial fibrillation using ablation (a procedure that targets the area of the heart causing the irregular rhythm).
- People who are willing and able to give their consent to participate and take part in all study-related assessments.
Who may not be able to join:
- People whose atrial fibrillation is caused by an underlying and treatable condition, such as an electrolyte imbalance, thyroid disease, or alcohol use.
- People whose left upper heart chamber (left atrium) is measured as too large on an ultrasound scan done within 3 months before the procedure (confirm with trial site for exact measurement threshold).
- People with severely reduced heart pumping function, measured by a heart ultrasound within 3 months before the procedure (confirm with trial site for exact threshold).
- People found to have a blood clot in the heart, detected by imaging tests done shortly before the procedure.
- People who have, or are expected to need, a pacemaker, defibrillator, or certain other heart devices or implants at the time of the procedure.
- People who have had any of the following within the 90 days before giving consent: a heart attack, unstable chest pain, heart surgery or a procedure on the heart's arteries, inflammation around the heart, bleeding in the digestive tract, a stroke, a mini-stroke (TIA), or a blood clot elsewhere in the body.
- People who are unable or unwilling to take blood-thinning medication.
- People who cannot stop taking certain heart rhythm medications (Class I or III antiarrhythmics) for reasons unrelated to their atrial fibrillation.
- People who are pregnant or breastfeeding.
- People with significantly reduced kidney function, or who have a history of kidney dialysis or a kidney transplant.
- People with other medical conditions that, in the treating doctor's opinion, would interfere with the study or increase risk to the participant.
- People with a life expectancy of less than 12 months.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Changsheng Ma, Doctor, Beijing Anzhen Hospital of the Capital University of Medical Sciences
Phone: 86-10-8574 2988
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Primary Effectiveness Endpoint with Treatment Success.; Primary Safety Endpoint with Safety events related to AF catheter ablation.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.